These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 28338353)
1. The burden of familial chylomicronemia syndrome: interim results from the IN-FOCUS study. Davidson M; Stevenson M; Hsieh A; Ahmad Z; Crowson C; Witztum JL Expert Rev Cardiovasc Ther; 2017 May; 15(5):415-423. PubMed ID: 28338353 [TBL] [Abstract][Full Text] [Related]
2. The burden of familial chylomicronemia syndrome: Results from the global IN-FOCUS study. Davidson M; Stevenson M; Hsieh A; Ahmad Z; Roeters van Lennep J; Crowson C; Witztum JL J Clin Lipidol; 2018; 12(4):898-907.e2. PubMed ID: 29784572 [TBL] [Abstract][Full Text] [Related]
3. The burden of familial chylomicronemia syndrome in Canadian patients. Gaudet D; Stevenson M; Komari N; Trentin G; Crowson C; Hadker N; Bernard S Lipids Health Dis; 2020 Jun; 19(1):120. PubMed ID: 32487261 [TBL] [Abstract][Full Text] [Related]
4. The burden of familial chylomicronemia syndrome from the patients' perspective. Gelrud A; Williams KR; Hsieh A; Gwosdow AR; Gilstrap A; Brown A Expert Rev Cardiovasc Ther; 2017 Nov; 15(11):879-887. PubMed ID: 28847199 [TBL] [Abstract][Full Text] [Related]
5. Familial Chylomicronemia Syndrome: A Clinical Guide For Endocrinologists. Falko JM Endocr Pract; 2018 Aug; 24(8):756-763. PubMed ID: 30183397 [TBL] [Abstract][Full Text] [Related]
6. The effect of volanesorsen treatment on the burden associated with familial chylomicronemia syndrome: the results of the ReFOCUS study. Arca M; Hsieh A; Soran H; Rosenblit P; O'Dea L; Stevenson M Expert Rev Cardiovasc Ther; 2018 Jul; 16(7):537-546. PubMed ID: 29889589 [TBL] [Abstract][Full Text] [Related]
7. Building a better understanding of the burden of disease in familial chylomicronemia syndrome. Ahmad Z; Halter R; Stevenson M Expert Rev Clin Pharmacol; 2017 Jan; 10(1):1-3. PubMed ID: 27771961 [No Abstract] [Full Text] [Related]
8. Familial chylomicronemia syndrome: Bringing to life dietary recommendations throughout the life span. Williams L; Rhodes KS; Karmally W; Welstead LA; Alexander L; Sutton L; J Clin Lipidol; 2018; 12(4):908-919. PubMed ID: 29804909 [TBL] [Abstract][Full Text] [Related]
9. The Chylomicronemia Syndrome Is Most Often Multifactorial: A Narrative Review of Causes and Treatment. Chait A; Eckel RH Ann Intern Med; 2019 May; 170(9):626-634. PubMed ID: 31035285 [TBL] [Abstract][Full Text] [Related]
10. PROMIS® and Neuro-QoL Fox RS; Peipert JD; Vera-Llonch M; Phillips G; Cella D Expert Rev Cardiovasc Ther; 2020 Apr; 18(4):231-238. PubMed ID: 32223345 [No Abstract] [Full Text] [Related]
11. Familial chylomicronemia syndrome: an under-recognized cause of severe hypertriglyceridaemia. Baass A; Paquette M; Bernard S; Hegele RA J Intern Med; 2020 Apr; 287(4):340-348. PubMed ID: 31840878 [TBL] [Abstract][Full Text] [Related]
12. Analyses of familial chylomicronemia syndrome in Pereira, Colombia 2010-2020: a cross-sectional study. Rodriguez FH; Estrada JM; Quintero HMA; Nogueira JP; Porras-Hurtado GL Lipids Health Dis; 2023 Mar; 22(1):43. PubMed ID: 36978188 [TBL] [Abstract][Full Text] [Related]
13. Familial chylomicronemia syndrome: A rare but devastating autosomal recessive disorder characterized by refractory hypertriglyceridemia and recurrent pancreatitis. Chyzhyk V; Brown AS Trends Cardiovasc Med; 2020 Feb; 30(2):80-85. PubMed ID: 31003756 [TBL] [Abstract][Full Text] [Related]
14. Characterizing familial chylomicronemia syndrome: Baseline data of the APPROACH study. Blom DJ; O'Dea L; Digenio A; Alexander VJ; Karwatowska-Prokopczuk E; Williams KR; Hemphill L; Muñiz-Grijalvo O; Santos RD; Baum S; Witztum JL J Clin Lipidol; 2018; 12(5):1234-1243.e5. PubMed ID: 30318066 [TBL] [Abstract][Full Text] [Related]
15. Pharmacological treatment options for severe hypertriglyceridemia and familial chylomicronemia syndrome. Chaudhry R; Viljoen A; Wierzbicki AS Expert Rev Clin Pharmacol; 2018 Jun; 11(6):589-598. PubMed ID: 29842811 [TBL] [Abstract][Full Text] [Related]
16. Qualitative development of the PROMIS Profile v1.0-Familial Chylomicronemia Syndrome (FCS) 28. Kaiser K; Fox RS; Perschon C; Vera-Llonch M; Alonso J; Cubells L; Cella D Qual Life Res; 2023 Feb; 32(2):605-614. PubMed ID: 36310187 [TBL] [Abstract][Full Text] [Related]
17. Estimating health state utilities associated with a rare disease: familial chylomicronemia syndrome (FCS). Matza LS; Phillips GA; Howell TA; Ciffone N; Ahmad Z J Med Econ; 2020 Sep; 23(9):978-984. PubMed ID: 32479143 [No Abstract] [Full Text] [Related]
18. Chylomicronemia: Differences between familial chylomicronemia syndrome and multifactorial chylomicronemia. Paquette M; Bernard S; Hegele RA; Baass A Atherosclerosis; 2019 Apr; 283():137-142. PubMed ID: 30655019 [TBL] [Abstract][Full Text] [Related]